These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo .
However , there were no significant differences between some dosages .
Compared with placebo , the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications .
Conclusions In consideration that the treatments of BTX-A were with minimal , local , and manageable adverse effects , this meta- analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U .
Purpose To assess the effectiveness and safety of botulinum toxin A ( BTX-A ) at different dosages for overactive bladder ( OAB ) .
Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes
Purpose Many trials do not measure quality -adjusted life years ( QALYs ) . Therefore , decision analysts often map condition-specific outcomes to preference scores . We estimated the relationship between changes in preference scores and commonly reported condition-specific outcomes in patients with urinary incontinence ( UI ) due to neurogenic detrusor overactivity . Methods In 59 patients recruited to a neurogenic UI trial , clinical outcomes ( UI episodes ) , condition-specific quality of life ( Incontinence Quality of Life Instrument ( I-QOL ) ) , and SF-6D preference scores were measured at enrollment and 24 weeks . We used multiple linear regression to estimate the impact on SF-6D scores of 50 ; 50–99 and 100 % reductions in UI episodes and a 10-point improvement in I-QOL . Results By 24 weeks , mean ( 95 % CI ) daily UI episodes fell by 0.85 ( 0.04 , 1.3 ) and mean I-QOL scores improved by 18 ( 12 , 24 ) . SF-6D scores increased by 0.03 ( 0.003 , 0.058 ) , due to improvements in role limitations . A ≥ 50 % reduction in UI episodes was achieved by 49 % of patients and corresponded to a 0.09 ( 0.02 , 0.16 ) SF-6D increase . A ≥ 10-point increase in I-QOL was attained by 65 % of patients and was associated with a 0.05 ( −0.02 , 0.12 ) SF-6D increase . Conclusions These estimates provide preliminary data for decision analysts wishing to map neurogenic UI outcomes to preference scores
These and other outcomes for effectiveness of BTX-A at different dosages in two observation periods indicate that a dose greater than 50 U is significantly more effective for certain symptoms of OAB compared with placebo .
However , there were no significant differences between some dosages .
Compared with placebo , the outcomes of total adverse events for NDO and for IDO show that doses of 300 U and 200 U for NDO are associated with more complications .
Conclusions In consideration that the treatments of BTX-A were with minimal , local , and manageable adverse effects , this meta- analysis demonstrates that BTX-A 200 U is recommended for management of NDO for short-term treatment for there was no significant difference from the larger dose of 300U .
Purpose To assess the effectiveness and safety of botulinum toxin A ( BTX-A ) at different dosages for overactive bladder ( OAB ) .